Opko Health (OPK) Stock: Buy, Sell, or Hold?
OPK - Opko Health Inc.
$1.56
-0.01 (-0.64%)
âŧ
5d:
-4.88%
30d:
-7.69%
90d:
+4.0%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When OPK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OPK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OPK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: OPK is currently trading at $1.56, which is considered fair relative to its 30-day fair value range of $1.51 to $1.66.
Technical Outlook: Technically, OPK is in a uptrend. The price is currently testing key support at $1.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OPK scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.38 (+180.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OPK is in a uptrend. The price is currently testing key support at $1.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OPK scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.38 (+180.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.51 -
$1.66
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (17/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.4% below Wall St target ($4.38)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.51 -
$1.66
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.55
Resistance Level
$1.75
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.67
Wall Street Target
$4.38
(+180.4%)
Revenue Growth (YoY)
4.3%
Earnings Growth (YoY)
-12.6%
Profit Margin
-12.4%
Share & Embed Analysis
Last updated: October 03, 2026 3:02 PM ET
Data refreshes hourly during market hours. Next update: 4:02 PM
Data refreshes hourly during market hours. Next update: 4:02 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OPK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$653 | 49 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 53 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 48 HOLD |
|
LH
Laboratory Corporation oâĻ |
STRONG BUY
20 analysts |
$345 | 67 BUY |
